FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065146937> ?p ?o ?g. }

• W2065146937 endingPage "151" @default.
• W2065146937 startingPage "147" @default.
• W2065146937 abstract "We analyzed the incidence of elevated serum levels of chromogranin A (CgA) (as marker of neuroendocrine activity) in nonmetastatic and metastatic prostate cancer populations.264 consecutive men with nonmetastatic prostate adenocarcinoma considered for radical prostatectomy (group 1) and 89 consecutive men with metastatic prostate adenocarcinoma (group 2) represented our population. In all 353 cases a blood sample for the determination of serum total PSA and CgA levels was obtained (RIA). Two different cut-off for elevated serum CgA levels were used: >60 and >90 ng/ml.In group 1, 35.0% of cases presented CgA levels >60 ng/ml and 6.4% >90 ng/ml. In group 2, 100% of cases presented CgA levels >60 ng/ml and 69.7% >90 ng/ml. The OR for CgA level >60 and >90 ng/ml significantly increased from nonmetastatic to metastatic cases (p = 0.0001). In group 1 the percentage of cases with CgA >60 ng/ml was 29.6% in Gleason score <or=7 (3 + 4) and 46.4% in Gleason score >or=7 (4 + 3) (p = 0.0001). In group 2, the percentage of cases with CgA >90 ng/ml was 51.8% in Gleason score <or=7 (3 + 4) and 77.4% in Gleason score >or=7 (4 + 3) (p = 0.0028).We describe a significant incidence of elevated serum levels of CgA either in nonmetastatic (using 60 ng/ml as cut-off) or in metastatic (using 90 ng/ml as cut-off) prostate adenocarcinoma cases." @default.
• W2065146937 created "2016-06-24" @default.
• W2065146937 creator A5016331942 @default.
• W2065146937 creator A5041823227 @default.
• W2065146937 creator A5046894081 @default.
• W2065146937 creator A5057812789 @default.
• W2065146937 creator A5060000517 @default.
• W2065146937 creator A5085151796 @default.
• W2065146937 creator A5090765157 @default.
• W2065146937 date "2009-01-01" @default.
• W2065146937 modified "2023-10-14" @default.
• W2065146937 title "Distribution of High Chromogranin A Serum Levels in Patients with Nonmetastatic and Metastatic Prostate Adenocarcinoma" @default.
• W2065146937 cites W1587021131 @default.
• W2065146937 cites W1759823501 @default.
• W2065146937 cites W1966553997 @default.
• W2065146937 cites W1972281874 @default.
• W2065146937 cites W1993302378 @default.
• W2065146937 cites W2001598371 @default.
• W2065146937 cites W2002546470 @default.
• W2065146937 cites W2010397777 @default.
• W2065146937 cites W2030291558 @default.
• W2065146937 cites W2077039324 @default.
• W2065146937 cites W2080140117 @default.
• W2065146937 cites W2094484039 @default.
• W2065146937 cites W2099493806 @default.
• W2065146937 cites W2102747963 @default.
• W2065146937 cites W2105103391 @default.
• W2065146937 cites W2114693836 @default.
• W2065146937 cites W2121953515 @default.
• W2065146937 cites W2140509267 @default.
• W2065146937 cites W2188742179 @default.
• W2065146937 cites W2342163288 @default.
• W2065146937 cites W2417465467 @default.
• W2065146937 cites W74496888 @default.
• W2065146937 doi "https://doi.org/10.1159/000200789" @default.
• W2065146937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19321999" @default.
• W2065146937 hasPublicationYear "2009" @default.
• W2065146937 type Work @default.
• W2065146937 sameAs 2065146937 @default.
• W2065146937 citedByCount "30" @default.
• W2065146937 countsByYear W20651469372012 @default.
• W2065146937 countsByYear W20651469372014 @default.
• W2065146937 countsByYear W20651469372015 @default.
• W2065146937 countsByYear W20651469372016 @default.
• W2065146937 countsByYear W20651469372017 @default.
• W2065146937 countsByYear W20651469372018 @default.
• W2065146937 countsByYear W20651469372019 @default.
• W2065146937 countsByYear W20651469372020 @default.
• W2065146937 countsByYear W20651469372021 @default.
• W2065146937 countsByYear W20651469372022 @default.
• W2065146937 crossrefType "journal-article" @default.
• W2065146937 hasAuthorship W2065146937A5016331942 @default.
• W2065146937 hasAuthorship W2065146937A5041823227 @default.
• W2065146937 hasAuthorship W2065146937A5046894081 @default.
• W2065146937 hasAuthorship W2065146937A5057812789 @default.
• W2065146937 hasAuthorship W2065146937A5060000517 @default.
• W2065146937 hasAuthorship W2065146937A5085151796 @default.
• W2065146937 hasAuthorship W2065146937A5090765157 @default.
• W2065146937 hasConcept C120665830 @default.
• W2065146937 hasConcept C121332964 @default.
• W2065146937 hasConcept C121608353 @default.
• W2065146937 hasConcept C126322002 @default.
• W2065146937 hasConcept C126894567 @default.
• W2065146937 hasConcept C204232928 @default.
• W2065146937 hasConcept C2776235491 @default.
• W2065146937 hasConcept C2779466945 @default.
• W2065146937 hasConcept C2780192828 @default.
• W2065146937 hasConcept C2781182431 @default.
• W2065146937 hasConcept C2908647359 @default.
• W2065146937 hasConcept C61511704 @default.
• W2065146937 hasConcept C71924100 @default.
• W2065146937 hasConcept C77231918 @default.
• W2065146937 hasConcept C90924648 @default.
• W2065146937 hasConcept C99454951 @default.
• W2065146937 hasConceptScore W2065146937C120665830 @default.
• W2065146937 hasConceptScore W2065146937C121332964 @default.
• W2065146937 hasConceptScore W2065146937C121608353 @default.
• W2065146937 hasConceptScore W2065146937C126322002 @default.
• W2065146937 hasConceptScore W2065146937C126894567 @default.
• W2065146937 hasConceptScore W2065146937C204232928 @default.
• W2065146937 hasConceptScore W2065146937C2776235491 @default.
• W2065146937 hasConceptScore W2065146937C2779466945 @default.
• W2065146937 hasConceptScore W2065146937C2780192828 @default.
• W2065146937 hasConceptScore W2065146937C2781182431 @default.
• W2065146937 hasConceptScore W2065146937C2908647359 @default.
• W2065146937 hasConceptScore W2065146937C61511704 @default.
• W2065146937 hasConceptScore W2065146937C71924100 @default.
• W2065146937 hasConceptScore W2065146937C77231918 @default.
• W2065146937 hasConceptScore W2065146937C90924648 @default.
• W2065146937 hasConceptScore W2065146937C99454951 @default.
• W2065146937 hasIssue "2" @default.
• W2065146937 hasLocation W20651469371 @default.
• W2065146937 hasLocation W20651469372 @default.
• W2065146937 hasOpenAccess W2065146937 @default.
• W2065146937 hasPrimaryLocation W20651469371 @default.
• W2065146937 hasRelatedWork W108895284 @default.
• W2065146937 hasRelatedWork W1967410728 @default.
• W2065146937 hasRelatedWork W1982503259 @default.

• next